2012 BIO International Convention
OTTAWA, Ontario--(BUSINESS WIRE)--BIOTECanada announced earlier today Therapure Biopharma Inc. (Therapure) has been named recipient of a Gold Leaf Award recognizing an outstanding early stage health company. Therapure is being recognized for the potential of their highly innovative drug discovery pipeline as well as for their unique biomanufacturing capabilities. Therapure is a contract development and manufacturing organization launched in 2008 and has rapidly grown to more than 120 employees. Therapure specializes in producing sophisticated biologics at its 130,000 square foot, cGMP bio-manufacturing facility in Mississauga, Ontario.
“Their scientific dedication is one we can all be proud. Therapure is providing paramount service to partners across Canada and internationally.”
“Therapure has distinguished themselves among their peers with incredible technology innovation,” commented Brad Thompson, Chair BIOTECanada. “Their scientific dedication is one we can all be proud. Therapure is providing paramount service to partners across Canada and internationally.”
“Therapure is privileged to receive this award and honoured to be recognized by our industry peers. Our growth is based on a strong foundation of protein manufacturing expertise as well as a rich pipeline of drug development candidates. We look forward to continued growth and expansion opportunities,” said Nick Green, President and CEO of Therapure.
Join us as we celebrate industry leadership during the BIO International Convention at the Boston Convention & Exhibition Center. The Gold Leaf Awards ceremony will take place at the Canada Café (booth number 735) June 19,2012 in Boston, MA at 4pm.
ABOUT THERAPURE
Since its launch into the Contract Development and Manufacturing Organization (CDMO) space in 2008, Therapure has achieved impressive growth including the execution of more than 30 service contracts with a broad spectrum of Canadian and international customers. In addition to its CDMO services, Therapure also has a portfolio of internal drug development programs focused on liver cancer, hepatitis C and chemotherapy-induced anemia. All of the products are pre-commercial with the lead program scheduled to begin Phase 1 in 2012. Therapure’s drug discovery pipeline is built on a deep knowledge and understanding of hematology. Therapure’s products are protected by an extensive portfolio of issued patents in the fields of protein drug conjugation and hematopoietic stem cells. Therapure is a key contributor in the creation of a centre of excellence in biotech manufacturing for Canada. With its unique services and pipeline products, Therapure represents a very significant opportunity to become a leading provider of CDMO services to the biological industry as well as a developing drug candidates targeted towards major unmet medical needs.
Contacts
BIOTECanada
Nadine Lunt
Senior Manager, Communications
613-230-5585 x257